Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 5Phase 3 3Phase 2/3 2Phase 1/2 2

Status

Completed 21Recruiting 9Unknown 8Terminated 7Not yet recruiting 4Active not recruiting 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Breast 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Carboplatin 106Cisplatin 97Paclitaxel 78pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 46Docetaxel 45Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 40Nivolumab 37Lenalidomide 37Specimen Handling 36Doxorubicin 36Rituximab 34Oxaliplatin 34Bevacizumab 33Magnetic Resonance Spectroscopy 32Fluorouracil 32atezolizumab 29Etoposide 29Vincristine 26Radiation 26Leucovorin 26Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × liposomal doxorubicin × Clear all
NCT02446600 2026-06-03

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
579 enrolled 17 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06619236 2026-06-02

RAINFOL-02

Genmab

Phase 3 Active not recruiting
448 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
340 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡